Speaker Profile

M.D., Associate Professor, Stanford University

Biography
Dr. Marinkovich received his dermatology training at Oregon Health Sciences University, and his research training in the laboratory of Dr. Robert Burgeson, who discovered type VII collagen. Dr. Marinkovich's early work led to the characterization of several key basement membrane components involved in epidermolysis bullosa, including laminin-332 and laminin-311. He later joined the faculty at Stanford University and served as an attending in the National EB Registry at Stanford University. He currently directs the Stanford Blistering Disease Clinic. Dr. Marinkovich’s laboratory has had a longstanding focus on the development of molecular therapy for various subtypes of epidermolysis bullosa.

Talk
Emerging Gene Therapies for Epidermolysis Bullosa
Dystrophic epidermolysis bullosa is a skin fragility disorder characterized by blistering in response to minor trauma. Advances in our understanding of epidermolysis bullosa pathophysiology and gene therapy vectors have led to successive advancements in dystrophic epidermolysis bullosa molecular correction, demonstrating that gene therapy for epidermolysis bullosa is safe and effective.


 Session Abstract – PMWC 2022 Silicon Valley


Track Chair:
Vanessa Soros, Graphite Bio

Sessions:

  • Gene & Cell Therapies Overview
    - Janice Chen, Mammoth
  • Advances in Gene & Cell Therapies
    Session Chair: Vanessa Soros, Graphite Bio
    - Mark McKee, Intellia Tx
    - Amy Simon, Beam Therapeutics
    - Eric Ostertag, Poseida Therapuetics
  • Translating CGT to the Clinic (PANEL)
    Session Chair: Nicole K. Paulk, UCSF
    - Matthew Porteus, Stanford
    - Eric Crombez, Ultragenyx Gene Therapy
    - Peter Francis, 4D Molecular Therapeutics
    - Erandi De Silva, Forge Biologics
    - Patrice Hugo, Q2 Solutions
  • PMWC Showcase
    - Yuri Fesko, Labcorp
    - Yan Zhang, Mission Bio
    - Anil Narasimha, Mekonos Inc.
    - Emily Anderson, Horizon, a PerkinElmer Company
    - Peter Marinkovich, Stanford
    - Jesse Salk, Twinstrand
    - William Shrader, AcureX Therapeutics
  • Past, Present and Future of CRISPR Where will CRISPR Take Us and How is the Technology Evolving to Realize its Full Potential (PANEL)
    Session Chair: Janice Chen, Mammoth
    - Kiana Aran, Cardea Bio
    - Mark McKee, Intellia Tx
    - Josh Lehrer, Graphite Bio